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From discovery to market, antibody therapeutics are developed using several expression platforms. Antibodies 
are often discovered from isolated mouse or human B-cells, engineered for affinity and specificity on the surface 
of phage, bacteria, or yeast, and manufactured in FDA-approved mammalian cell lines. This functional 
engineering detour in non-mammalian platforms introduces the opportunity to adversely impact expression and 
stability of the final product in the mammalian production cell line. To address this shortcoming, a CHO cell 
display platform was developed in which the antibody therapeutic can be engineered in the CHO manufacturing 
cell line, streamlining the process (Fig.1). CHO cell display of an antibody Fab fragment was developed and 
optimized using a semi-stable episomal system capable of maintenance of a transfected plasmid for several 
weeks, which allows multiple rounds of flow cytometric sorting and regrowth of promising clones. 
 
To test the utility of the CHO surface 
display platform and screening process, 
a randomly mutated library was made 
from a low affinity antibody parent and 
screened for improved binding. The 
target antigen for this test case was 
HER2, a well-characterized receptor 
over-expressed in approximately 20% 
of breast cancer cases. The anti-HER2 
library was subjected to two rounds of 
flow cytometric screening for improved 
antigen binding while controlling for 
expression level. This resulted in nine 
unique clones, of which six exhibited 
improved HER2 binding relative to the 
parent upon subsequent analysis of 
individual clones in the displayed 
format. Seven of the nine sequences 
were sub-cloned for CHO cell 
expression as full-length, soluble antibodies and characterized for expression level, affinity, and stability. All 
seven full-length antibodies were expressed at levels and with stabilities comparable to the parent, and several 
had improved binding affinity relative to the parent. 
 
Although the anti-HER2 antibody 4D5 (Herceptin) has been an effective breast cancer therapeutic, it exhibits 
undesired binding to myocardiocytes, which can result in adverse reactions to therapy. The low pH tumor 
microenvironment provides an opportunity to engineer the antibody to selectively bind HER2 at low pH (~6) and 
avoid binding non-target cells residing in the neutral (~pH 7.4) normal tissue microenvironment. A library of 4D5 
Fab variants was displayed on CHO cells and screened for preferential binding to HER2 under low pH 
conditions. Data on clonal expression and pH-dependent ligand binding will be shown. 
 
In both the CHO surface display proof-of-principle affinity maturation and low pH selective binding screen 
presented, the antibodies were improved in a commonly used manufacturing cell line, which is expected to limit 
the need for further expression optimization. The CHO surface display technology and techniques represent a 
generalizable method for the streamlined development of therapeutic antibodies. 
 
 
Figure 1. Top, overview of the traditional discovery, development 
and manufacturing steps used for Herceptin and Humira, starting 
with B cells from immunized mice, transfer of variable region genes 
into bacteria or yeast for affinity engineering & humanization and 
finally into CHO cells for production. Bottom, the proposed 
streamlined approach in which engineering takes place in the CHO 
cell production host. 
